IL100402A0 - Use of il-4 to enhance immune response to immunogens in vaccines - Google Patents

Use of il-4 to enhance immune response to immunogens in vaccines

Info

Publication number
IL100402A0
IL100402A0 IL100402A IL10040291A IL100402A0 IL 100402 A0 IL100402 A0 IL 100402A0 IL 100402 A IL100402 A IL 100402A IL 10040291 A IL10040291 A IL 10040291A IL 100402 A0 IL100402 A0 IL 100402A0
Authority
IL
Israel
Prior art keywords
immune response
immunogens
vaccines
vaccine
enhance immune
Prior art date
Application number
IL100402A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL100402A0 publication Critical patent/IL100402A0/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/08—Clostridium, e.g. Clostridium tetani
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A61K2039/55527—Interleukins
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL100402A 1990-12-19 1991-12-17 Use of il-4 to enhance immune response to immunogens in vaccines IL100402A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US62980090A 1990-12-19 1990-12-19

Publications (1)

Publication Number Publication Date
IL100402A0 true IL100402A0 (en) 1992-09-06

Family

ID=24524543

Family Applications (1)

Application Number Title Priority Date Filing Date
IL100402A IL100402A0 (en) 1990-12-19 1991-12-17 Use of il-4 to enhance immune response to immunogens in vaccines

Country Status (20)

Country Link
EP (1) EP0563254B1 (de)
JP (1) JPH06503830A (de)
CN (1) CN1063227A (de)
AT (1) ATE129900T1 (de)
AU (1) AU9161591A (de)
CA (1) CA2098726A1 (de)
CZ (1) CZ119993A3 (de)
DE (1) DE69114519T2 (de)
DK (1) DK0563254T3 (de)
ES (1) ES2079851T3 (de)
FI (1) FI932759L (de)
GR (1) GR3018820T3 (de)
HU (1) HUT68529A (de)
IE (1) IE70453B1 (de)
IL (1) IL100402A0 (de)
OA (1) OA09863A (de)
PT (1) PT99838A (de)
SK (1) SK59393A3 (de)
WO (1) WO1992011030A1 (de)
ZA (1) ZA919907B (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5206345A (en) * 1990-08-02 1993-04-27 Fred Hutchinson Cancer Research Center Il-4 and tnf induce mab 6g10-recognized expression on bone marrow stromal cells
US7449186B1 (en) 1990-08-02 2008-11-11 Fred Hutchinson Cancer Research Center Methods of blocking the interaction between stromal cells and hemopoietic cells with anti-VCAM-1 antibodies
US5827670A (en) * 1990-08-02 1998-10-27 Fred Hutchinson Cancer Research Center Methods of isolating and detecting bone marrow stromal cells with VCAM-1-specific antibodies
WO1994003202A1 (en) * 1992-08-10 1994-02-17 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Interleukin-4 stimulated t lymphocyte cell death
WO1994028871A1 (en) * 1993-06-07 1994-12-22 Endocon, Inc. Implant stimulated cellular immunity
WO1995027500A1 (en) * 1994-04-08 1995-10-19 Brigham And Women's Hospital TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES
US6660258B1 (en) 1997-05-09 2003-12-09 Pharma Pacific Pty Ltd Oromucosal cytokine compositions and uses thereof
FR2769505B1 (fr) * 1997-10-10 2000-06-30 Michael Gerard Tovey Compositions de cytokines a administrer a la muqueuse buccale, et leurs utilisations
RU2138288C1 (ru) * 1998-06-03 1999-09-27 Акционерное общество открытого типа "Биомед" им.И.И.Мечникова Способ получения полимерной фракции столбнячного анатоксина
GB201821207D0 (en) 2018-12-24 2019-02-06 Tcer Ab Immunotherapy therapy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT83761B (pt) * 1985-11-19 1989-06-30 Schering Biotech Corp Metodo para a producao de interleuquina-4 de mamifero
DE3751664T2 (de) * 1986-08-01 1996-06-05 Commw Scient Ind Res Org Rekombinanter impfstoff
DE69018990T2 (de) * 1989-07-14 1995-12-14 Praxis Biolog Inc Stabile interleukine enthaltende impfstoffzusammensetzungen.
ZA912037B (en) * 1990-03-21 1992-03-25 Schering Corp Use of il-4 to enhance immune response to infectious antigenic challenges

Also Published As

Publication number Publication date
AU9161591A (en) 1992-07-22
IE914436A1 (en) 1992-07-01
FI932759A7 (fi) 1993-06-16
SK59393A3 (en) 1994-03-09
HU9301797D0 (en) 1993-10-28
DE69114519D1 (de) 1995-12-14
EP0563254B1 (de) 1995-11-08
FI932759A0 (fi) 1993-06-16
ES2079851T3 (es) 1996-01-16
GR3018820T3 (en) 1996-04-30
ZA919907B (en) 1992-08-26
IE70453B1 (en) 1996-11-27
OA09863A (en) 1994-08-15
ATE129900T1 (de) 1995-11-15
DE69114519T2 (de) 1996-04-04
PT99838A (pt) 1992-12-31
HUT68529A (en) 1995-06-28
CA2098726A1 (en) 1992-06-20
EP0563254A1 (de) 1993-10-06
WO1992011030A1 (en) 1992-07-09
JPH06503830A (ja) 1994-04-28
FI932759L (fi) 1993-06-16
CZ119993A3 (en) 1994-02-16
DK0563254T3 (da) 1996-02-12
CN1063227A (zh) 1992-08-05

Similar Documents

Publication Publication Date Title
MX9304089A (es) Uso de gm-csf como una vacuna adyuvante.
UA40597C2 (uk) Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
NZ218825A (en) Use of low dosages of interferon as adjuvants for vaccines
MY110086A (en) Herpes simplex virus vaccines comrpising glycoprotein d and 3d-mpl
EP0438803A3 (en) Vaccines against cancer and infectious diseases
GR3017497T3 (en) Recombinant DNA-derived bordetella toxin subunit analogs.
CA2169764A1 (en) Dampening of an immunodominant epitope of an antigen for use in plant, animal and human vaccines and immunotherapies
CA2116562A1 (en) Morphogen-Induced Modulation of Inflammatory Response
GR3018820T3 (en) Use of il-4 to enhance immune response to immunogens in vaccines.
LU90203I2 (fr) Anatoxine diphtérique anatoxine tétanique trois antigènes coquelucheux purifiés (toxine pertussique tp hémagglutinine filamenteuse (haf) et pertactine (protéine de membrane externe 69 kd) et le principal antigène de surface du virus de l'hépatite b (vhb) purfié (infanrix hepb) et ses dérivés pharmaceutiquement acceptables
CO4910171A1 (es) Vacunas comprendiendo bajas dosis de antigenos de difteria, tetano y tos ferina acelular ( dtpa )
DE69333448D1 (en) P53 impfstoff
EP0498804A4 (en) A method of vaccine or toxoid preparation and immunization by colonization with recombinant microorganisms
EP0833903A4 (de) Multivalenter impstoff gegen bovines coronavirus und methode zur behandlung einer infektion mit bovinem coronavirus
GR3019018T3 (en) Use of il-4 to enhance immune response to infectious antigenic challenges
TW263437B (de)
CA2331086A1 (en) Hepatitis vaccine
EP0414816A4 (en) Induction of tolerance to a foreign antigen
NO892015L (no) Fremgangsmaate for fremstilling av et legemiddel.
NZ501427A (en) Vaccine compositions comprising the Helicobacter pylori FlgE (flagella) polypeptide and a mucosal adjuvant
IT1217314B (it) Nonapeptide sintetico ad attivita'adiuvante capace di potenziare in vivo la risposta anticorporale
RU93043610A (ru) Фармацевтическая композиция для усиления первичной иммуно-реакции у млекопитающих, способ усиления первичной иммуно-реакции и применение интерлейкина-4 для усиления первичной иммуно-реакции у млекопитающих, набор лекарственных средств
OA08974A (en) New immunologically active synthetic peptides useful for preparing an antimalarial vaccine
Rethy Jr et al. The purification-method-dependent immunogenicity of diphtheria toxoid. II. The human immunogenicity of differently purified toxoids.
Báthori et al. Immuno-modulation with inactivated bacterium-suspensions or derivatives. VI. The immuno-adjuvanting activity of liposomes combined with lipid-A and B. pertussis vaccine.